Tulane University School of Medicine

Health care stakeholders prioritize patient needs, leverage innovations, and allocate resources equitably. Experts discuss value-based cancer care, holistic CKM syndrome management, supportive care gaps for older adults with MDS/AML, financial aid for cancer patients, and e-cigarette health risks among youth.

The MajesTEC-1 trial evaluated teclistamab in R/R multiple myeloma patients, showing a 63% ORR and 46% CR rate. Median duration of response was 24 months, with PFS at 11 months and OS at 22 months. Safety concerns include cytopenias and cytokine release syndrome, addressed with supportive care and IVIG prophylaxis.

Healio Dermatology's top story in November focused on the CMS's 2025 physician fee schedule cuts and their impact on patient access, with FDA approvals for Emrosi, Bimzelx, and Microlyte Ag/Lidocaine also making headlines.

Real-world data on teclistamab use in RRMM show decreasing hospitalization days, CRS incidence at 41%, and potential for less frequent dosing without affecting outcomes. Outpatient step-up dosing is feasible with proper patient selection and education.

At the 44th Annual Fall Clinical Dermatology Conference, Dr. Andrea Murina discussed the evolving therapeutic landscape of Hidradenitis Suppurativa (HS), emphasizing the importance of early biologic therapy for patients with severe symptoms. Murina highlighted current treatments like adalimumab and secukinumab, and future prospects such as bimekizumab, which targets IL-17 A and F, showing potential for higher clearance rates in HS patients.

UC San Diego study finds men and women use different biological systems to relieve chronic lower back pain; men rely on endogenous opioids, while women use non-opioid pathways. This suggests a need for sex-specific pain therapies to improve outcomes and reduce opioid misuse.

Speakers at the Cardiometabolic Health Congress highlighted recent FDA regulatory moves in hypertension, lipid, and diabetes therapies, including approvals and rejections.

Blocking opioid system with naloxone inhibited meditation-based pain relief in men, but increased it in women. Chronic pain sufferers experienced more relief than healthy participants. Study highlights need for sex-specific pain therapies to improve outcomes and reduce opioid reliance.

The EAP for [177Lu]Lu-PSMA-617 in PSMA-positive mCRPC patients showed similar PSA RRs and OS to the VISION trial, with comparable safety profiles despite more advanced disease and heavier ARSI treatment in EAP patients.